Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Xuanzhu Biopharmaceutical Co's enterprise value is €631.26 Mil.
Xuanzhu Biopharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-26.06 Mil. Therefore, Xuanzhu Biopharmaceutical Co's EV-to-EBITDA for today is -24.22.
The historical rank and industry rank for Xuanzhu Biopharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
FRA:V59'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -135.03 Med: -58.6 Max: -18.45
Current: -24.11
During the past 3 years, the highest EV-to-EBITDA of Xuanzhu Biopharmaceutical Co was -18.45. The lowest was -135.03. And the median was -58.60.
FRA:V59's EV-to-EBITDA is ranked worse than 100% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.255
vs FRA:V59: -24.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Xuanzhu Biopharmaceutical Co (FRA:V59) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xuanzhu Biopharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Xuanzhu Biopharmaceutical Co's share price for today is €1.306.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Xuanzhu Biopharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.064.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co EV-to-EBITDA Chart
Xuanzhu Biopharmaceutical Co Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-EBITDA
0.00
0.00
-150.26
Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
EV-to-EBITDA
0.00
0.00
0.00
0.00
-150.26
FRA:V59 vs ZTS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xuanzhu Biopharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xuanzhu Biopharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xuanzhu Biopharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Xuanzhu Biopharmaceutical Co's EV-to-EBITDA falls into.
Xuanzhu Biopharmaceutical Co's current Enterprise Value is €631.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Xuanzhu Biopharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-26.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co (FRA:V59) has a EV-to-EBITDA of -24.22 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Xuanzhu Biopharmaceutical Co. According to the industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #999999 out of 736 companies in the Drug Manufacturers industry.
Is Xuanzhu Biopharmaceutical Co's EV-to-EBITDA too high?
Xuanzhu Biopharmaceutical Co's current EV-to-EBITDA is -24.22. Based on the distribution chart, Xuanzhu Biopharmaceutical Co ranks #999999 out of 736 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #999999 out of 736 companies for EV-to-EBITDA. This places Xuanzhu Biopharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.26, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Xuanzhu Biopharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xuanzhu Biopharmaceutical Co's current EV-to-EBITDA is -24.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a current EV-to-EBITDA of -24.22. The current EV-to-EBITDA is -24.22. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (FRA:V59), the current EV-to-EBITDA is -24.22 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score
Get the complete analysis for FRA:V59
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V59 has been successfully added to your 
